PDCD1 and cervical cancer: Monoclonal antibodies targeting PD-1/programmed death ligand, such as pembrolizumab, have already been widely assessed in clinical trials and are currently approved for the treatment of advanced cervical cancer (Borcoman and Le Tourneau, 2017; Chen et al., 2017; Chung et al., 2019; Dyer et al., 2019).